hepatitis B
Global study calls for overhaul of hepatitis B care to meet WHO targets
August 21, 2025Medical Communications, Medical/ Scientific Writing Hepatology, World Health Organisation, hepatitis B, liver damage, medical study
A major global study has warned that current models of hepatitis B care are failing patients and could jeopardise the …
GSK gains FDA Fast Track designation for chronic hepatitis B treatment
February 12, 2024Medical Communications FDA, GSK, Hepatology, fast track designation, hepatitis B
GSK has announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for bepirovirsen, an investigational …
GSK enters agreement for license for JNJ-3089 for development of bepirovirsen
November 2, 2023Medical Communications Arrowhead Pharmaceuticals, GSK, Infections and infestations, Janssen, hepatitis B
GSK and Arrowhead Pharmaceuticals have announced that they have come to an agreement with Janssen Pharmaceuticals, a Johnson & Johnson …
First patient dosed in phase 1 study for chronic hepatitis B treatment
August 31, 2023Medical Communications Chronic Diseases, ISA Pharmaceuticals, ISA104, clinical trial, hepatitis B
ISA Pharmaceuticals has announced that the first patient has been dosed in its phase 1 HEB-PEP study, assessing the use …
Dynavax’s hepatitis B vaccine gets EU approval
February 23, 2021Manufacturing and Production EU, Vaccine, hepatitis B
The European Commission (EC) has granted marketing authorisation Dynavax Technologies Corporation’s HEPLISAV B vaccine for the active immunisation against hepatitis …
Arbutus Biopharma moves to terminate development of chronic hepatitis B therapy after trial failure
October 4, 2019Medical Communications, Research and Development Arbutus Biopharma, hepatitis B, pharma
Arbutus Biopharma has announced its decision to terminate the development of its oral capsid inhibitor, known as AB-506, in the …
Hep-B vaccine four-year battle for FDA approval is finally won
November 10, 2017Medical Communications, Sales and Marketing biotech, drugs, dynavax, hepatitis B, pharma, pharmaceutical
Dynavax had said it was the last throw of the dice for its hepatitis B vaccine, Hepislav-B – the data …
Global shortage of hep B vaccine hits UK
August 9, 2017Manufacturing and Production, Research and Development GSK, MSD, biotech, drugs, hep b, hepatitis B, pharma, pharmaceutical
Only last week it was revealed that the UK would administer all babes with the hepatitis B vaccine to reduce …
FDA warns that certain hepatitis C drugs can have serious side-effects
October 5, 2016Medical Communications, Research and Development FDA, hepatitis B, hepatitis C
The FDA has issued a warning to patients who are currently taking drugs to treat hepatitis C that they may …
Roche cuts ties with Inovio in hepatitis B development
August 3, 2016Research and Development Inovio, Roche, hepatitis B
Inovio Pharmaceuticals has announced that it will independently continue development of hepatitis B immunotherapy, INO-1800, after Swiss drugmaker Roche issued …
FDA to review investigational hepatitis B vaccine
April 1, 2016Medical Communications, Research and Development dynavax, hepatitis B, vaccines
Dynavax Technologies (NASDAQ: DVAX) says the FDA has accepted for review the company’s investigational adult hepatitis B vaccine, HEPLISAV-B. The FDA has set …
Gilead success in late-stage hepatitis B trials
January 5, 2016Research and Development, Sales and Marketing Gilead, hepatitis B, phase III
Two Phase III trials evaluating Gilead treatments in chronic hepatitis B virus (HBV) infection have met their primary objectives, showing …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
